The Role of Glucose-Dependent Insulinotropic Polypeptide in the Pathological Glucose Homeostasis Of Type 1 Diabetes

• Status: Completed
• Trial end date: 2019-12-31
• Target enrollment: 0
• Participant gender: Male

Summary

In the present project the investigators will evaluate whether glucagonotropic properties of the gut-derived incretin hormone glucose-dependent insulinotropic polypeptide (GIP) may be utilized as a safeguard against hypoglycemia in the daily life of participants with type 1 Diabetes

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Steno Diabetes Center; Steno Diabetes Center Copenhagen
• Treatments: Gastric Inhibitory Polypeptide

Criteria

Inclusion Criteria:

• Body mass index between 20 and 27 kg/m2

• T1D (diagnosed according to the criteria of the World Health Organization) with HbA1c <69 mmol/mol (<8.5%)

• Treatment with a stable insulin regimen ≥3 months

• T1D duration between 2 and 15years

• C-peptide negative (C-peptide ≤ 16 ng/ml)

• Informed consent

Exclusion Criteria:

• Anemia (hemoglobin outside normal range)

• Known liver disease and/or ALAT and/or ASAT > 2 times normal values

• Estimated glomerular filtration rate (eGFR) ≤60 ml/min/1.73 m2 or albuminuria

• Prior Cardiovascular events and/or abnormal heart rate/blood pressure

• Use of anti-diabetic medicine (other than insulin), corticosteroids or other drugs affecting glucose metabolism during the study period or within 30 days prior to randomization

• Any physical or psychological condition that the investigator feels would interfere with trial participation